Sentinel lymph node biopsy has been shown in the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial to be sufficient for women with early-stage breast cancer and 1 to 2 positive sentinel lymph nodes; however, many patients received non-specified radiotherapy. Practice patterns since the publication of this study were analyzed using a large nationwide database showing a decrease in completion axillary lymph node dissection and marked variability in radiotherapy field design. Background: For clinical T1-2N0 breast cancer, sentinel lymph node biopsy (SLNB) has been shown in American College of Surgeons Oncology Group (ACOSOG) Z0011 to be sufficient for women with 1 to 2 positive sentinel lymph nodes with no added benefit for completion axillary lymph node dissection (ALND). Z0011 specified whole breast radiotherapy (RT) using standard tangential fields; however, later analysis showed variation in field design. We assessed nationwide practice patterns and examined factors associated with patients undergoing completion ALND and subsequent radiation field design. Patients and Methods: Women with clinical T1-2N0 breast cancer who underwent breast-conserving surgery, axillary staging, and whole breast RT in 2012 to 2013 were identified in the National Cancer Database. Multivariable logistic regression modeling was used to examine axillary management and RT, adjusting for demographic and clinicopathologic factors. Results: Among 83,555 patients meeting criteria, 9.3% underwent upfront ALND, 75.8% underwent SLNB only, and 14.9% underwent SLNB with completion ALND. From 2012 to 2013, upfront SLNB increased from 90.1% to 91.4% (odds ratio, 1.14; P < .001). Among 9474 patients that underwent SLNB with 1 to 2 positive sentinel nodes, 31.2% received completion ALND. Among patients with 1 to 2 positive sentinel nodes, SLNB increased from 65.8% to 72.1% from 2012 to 2013 (P < .001). For patients with 1 to 2 positive lymph nodes that underwent SLNB only, 63.4% underwent breast RT, whereas 36.6% received breast and nodal RT. Conclusions: Nationwide practice patterns of axillary management vary. Despite an increasing rate of SLNB, many patients still receive upfront and completion ALND. Furthermore, there is significant variation in RT field design, and modern treatment guidelines are warranted for this patient population.
Introduction
The surgical management of breast cancer has long been an area of great debate, heavily focused on the extent of surgical resection deemed acceptable. The proposal that less radical surgery may be Axillary staging and management were previously accomplished through the use of ALND, which carries a 10% to 20% risk of lymphedema. 2 The results of the NSABP B-32 trial demonstrated equivalence of SLNB followed by immediate conventional ALND compared with SLNB alone if sentinel lymph nodes (SLNs) were negative. Overall survival, disease-free survival, and regional control were equivalent between groups, demonstrating the feasibility of no further axillary dissection following a negative SLNB. 3 This less invasive technique has shown decreased morbidity and improved sensitivity in detecting occult nodal disease. 4 The American College of Surgeons Oncology Group (ACO-SOG) Z0011 trial investigated the need for further axillary dissection among patients with 1 to 2 positive SLNs undergoing segmental mastectomy. ACOSOG Z0011 was a phase III non-inferiority trial in patients with clinical T1-T2N0 breast cancer who underwent SLNB and had 1 to 2 positive SLNs. Patients were randomized to no additional axillary surgery or completion ALND. 5 Over 90% of patients received adjuvant systemic therapy with no differences between groups. Per protocol, patients were to undergo whole-breast RT following breast conservation surgery with opposing tangential fields. Initial results were published in February 2011 with a median follow-up of 6.3 years, showing no significant difference in overall survival, disease-free survival, and local or regional recurrence among women with 1 to 2 positive SLNs undergoing completion ALND versus SLNB only. This landmark trial altered the treatment paradigm for axillary management and led to the recommendation by the National Comprehensive Cancer Network and the American Society of Clinical Oncology to recommend no additional axillary surgery beyond SLNB for women meeting ACOSOG Z0011 inclusion criteria planning on receiving RT. 6, 7 This practice-changing study counters the argument that completion ALND is needed in patients with 1 to 2 positive SLNs following segmental mastectomy. The ACOSOG Z0011 protocol specified that patients receive whole-breast RT using standard tangential fields and specifically prohibited a supraclavicular field of directed nodal radiation; however, there was no blinding of radiation oncologists, who had discretion over treatment field design. 4 A study analyzing the field design in Z0011 showed that there were differences in radiation delivery noted upon review of 228 detailed RT records. 8 Within the radiation oncology community, there has been a question as to the optimal RT field design in patients with low-volume axillary disease who do not receive a completion ALND, thus failing to provide important pathologic information that has traditionally been available to the radiation oncologist to aid in guiding treatment. 9 Given the above, we sought to investigate practice patterns including surgical management and radiation field design for patients with clinically node-negative breast cancer undergoing breast-conserving therapy with 1 to 2 positive SLNs, using the National Cancer Database (NCDB). Notably, data on the scope of regional lymph node surgery have been found to under-report SLNB procedures either alone or with ALND, and reviews by the Commission on Cancer, the Centers for Disease Control and Prevention's National Program of Cancer Registries, and the National Cancer Institute's Surveillance, Epidemiology, and End Results Program, all confirmed miscoding of this data element. Revised coding rules were recently employed for cases diagnosed in 2012 and later, providing crucial sentinel node data for the desired study population in the period following the publication and dissemination of results from ACOSOG Z0011, making this study possible. 10 
Patients and Methods

Data Source
The NCDB is a joint project of the American College of Surgeons and the American Cancer Society that draws data from more than 1500 accredited cancer programs, accounting for 70% of all newly diagnosed cancer cases in the United States. It includes a modern cohort of patients treated from 2012 to 2013, and thus who were treated following the publication of the results of ACOSOG Z0011. Advantages of the NCDB over the Surveillance, Epidemiology, and End Results database include data for younger patients, pathologic factors, chemotherapy use, RT volumes, and medical comorbidities, which were included in our analysis. Another advantage of using the NCDB is the inclusion of many patients treated in varying settings including academic and community settings.
Patient Selection
Women with clinical T1-T2N0M0 invasive breast cancer with 1 to 2 positive SLNs who underwent breast conservation surgery, axillary management, and adjuvant RT from 2012 to 2013 were included in this analysis. Axillary management included SLNB alone, SLNB followed by ALND, or ALND. All patients were required to have received surgery at a Commission on Cancer facility and adjuvant external beam RT. RT volumes included whole breast RT or whole breast plus regional lymph node RT. Interrogation of the NCDB yielded a total of 83,555 patients who met the search parameters.
Definition of Variables
Patient and treatment characteristics included facility type, age, ethnicity, insurance status, median income, education, geographic location, Charlson-Deyo comorbidity score, year of diagnosis, breast cancer laterality, grade, clinical and pathologic tumor size, number of nodes positive (1 or 2), clinical and pathologic stage, presence of lymphovascular invasion, hormone receptor subtype, surgical margin negativity, radiation technique (3D or intensity-modulated RT), receipt of adjuvant chemotherapy, and receipt of endocrine therapy. Patient exclusion criteria were similar to ACOSOG Z0011 criteria: women with 3 or more positive SLNs, mastectomy, matted nodes, gross extranodal disease, or who had received neoadjuvant systemic therapy.
Statistical Analysis
We calculated summary statistics using frequencies and proportions for categorical variables. We compared patient demographic, prognostic, and facility characteristics between treatment groups using the c 2 test. Univariate and multivariable logistic regression analyses were employed to determine the factors independently associated with receipt of each treatment (ie, separate models for each treatment of interest). Factors of interest included facility type, facility location, age, race/ethnicity, insurance status, income, education, urban/rural status, Charlson-Deyo comorbidity score, year of diagnosis, laterality, grade, tumor size, number of e478 -Clinical Breast Cancer August 2018
Axillary Management and Radiotherapy regional lymph nodes examined, number of positive lymph nodes, clinical T stage, pathologic T stage, pathologic N stage, analytic stage, lymphovascular invasion, hormone receptor subtype, BloomRichardson grade, surgical margins status, chemotherapy, and hormone therapy. Factors that were significant (P < .05) in the univariate analyses were included in the multivariable models. Three separate multivariable logistic regression models were constructed in patient subgroups of interest including: factors associated with patients undergoing SLN biopsy with or without ALND compared with upfront ALND; factors associated with patients undergoing completion ALND after 1 to 2 positive sentinel nodes; and factors associated with patients with 1 to 2 positive sentinel nodes who undergo SLNB only, who then go on to receive adjuvant RT to the breast and regional lymph nodes compared with breast RT alone. Patients with missing covariate data were excluded from the multivariable regression models. Co-linearity between covariates in the models was evaluated prior to the formulation of the final multivariable models. Crude and adjusted odds ratios (ORs) with 95% confidence intervals were reported. C-statistics were calculated to evaluate the discriminative capacity of each multivariable model. All P-values are 2-sided with statistical significance evaluated at the 0.05 alpha level. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC). Institutional review board approval was waived for this study. (Table 1) . Patients with triple-negative disease were not more likely to undergo upfront ALND. The rate of upfront SLNB AE ALND in patients showed an absolute increase over 2012 to 2013 from 90.1% to 91.4% (OR, 1.14; P < .001). The rate of patients undergoing SLNB AE ALND, rather than upfront ALND, was greater in patients with clinical T1 disease (91.3% vs. 89.3%, respectively; OR, 1.12; P ¼ .01).
Results
Independent
Independent Factors Associated With Patients Undergoing Completion ALND After 1 to 2 Positive Sentinel Nodes
Factors associated with completion ALND in patients who had 1 to 2 positive SLNs at the time of SLNB were determined. Of 63,346 patients who underwent SLNB, there were 9474 (15.0%) with 1 to 2 positive SLNs. Among these patients, a total of 68.8% (N ¼ 6520) underwent no further axillary dissection (SLNB only) and 31.2% (N ¼ 2954) received SLNB followed by completion axillary dissection (SLNB þ ALND). Baseline characteristics available in Supplemental Table 2 in the online version. On multivariable logistic regression, statistically significant factors associated with patients with 1 to 2 positive sentinel nodes undergoing completion ALND compared to SLNB only were facility type and location, age, race, year of diagnosis, and the number of positive sentinel nodes ( Table 2 Among patients who had 1 to 2 positive sentinel nodes at the time of SLNB, and no completion axillary dissection, we investigated the RT volumes, whole breast RT versus whole breast plus regional nodal RT. Among these patients, 63.4% (N ¼ 4136) underwent whole breast RT and 36.6% (N ¼ 2384) received whole breast and regional nodal RT. Baseline characteristics available in Supplemental Table 3 in the online version. On multivariable logistic regression, statistically significant factors associated with patients receiving whole breast and regional nodal RT compared with breast RT alone were facility type and location, race, insurance status and median income, and the number of positive sentinel nodes (Table 3) . Regarding the number of positive sentinel nodes, patients with 2 positive SLNs had a greater likelihood of receiving RT to the breast and regional lymphatics compared with the breast alone (OR, 1.96; P < .001). Community cancer programs have a greater rate of treating the breast and regional lymphatics (OR, 1.35; P ¼ .002). The treatment year that patients received RT was not significant.
Discussion
The present study reports the influence of the dissemination of ACOSOG Z0011 utilizing a prospective nationwide database analyzing the surgical and RT management of patients with earlystage clinically node-negative breast cancer with low-volume axillary disease. These results show an absolute increase in the rate of upfront SLNB of 1.3% (OR, 1.14; P < .001). Despite the reduction in upfront ALND, almost 9% of patients meeting the Z0011 entry criteria underwent ALND upfront, rather than SLNB.
The NSABP B-32 trial is a large phase III trial showing equivalence in disease outcomes between upfront ALND alone versus upfront SLNB with completion dissection for positive SLNs found at the time of SLNB. With regards to reliability, SLNB demonstrated a 97.2% technical success rate of SLN removal with a 9.8% false-negative rate. 11 Morbidity data from the B-32 trial at 3 years showed reduced residual shoulder abduction deficits, arm volume differences, arm numbness, and arm tingling in the SLNB arm.
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These results are concordant with other studies also evaluating SLNB versus ALND, including the ALMANAC (Axillary Lymphatic Mapping Against Nodal Axillary Clearance) trial, which demonstrated reduced morbidity with SLNB rather than ALND. 13 Despite this, our findings show that nearly 10% of all patients with clinically node-negative breast cancer still receive upfront ALND. Axillary Management and Radiotherapy
One of the criticisms of ACOSOG Z0011 was that the initial report had a median follow-up of only 6.3 years, which was arguably insufficient to assure non-inferiority, as differences in overall survival may only show up with longer term follow-up. 14 The recent publication of the long-term outcomes, now with a median followup of 9.25 years, continues to show no significant difference in cumulative incidence of local, regional, or locoregional recurrences, maintaining the original conclusion that SLNB without completion ALND offers excellent regional control for select patients with lowvolume axillary disease who receive breast conservation therapy followed by whole breast RT. 15 Since the publication of ACOSOG Z0011's results in 2011, various institutional reports have shared their axillary management practice patterns. Analysis of the ALND rate following SLNB in 3 tertiary referral care centers showed a significantly reduced number of completion ALNDs performed in SLN-positive patients in the post-Z0011 period (71.4 %) compared with the pre-Z011 period (93.7%; P ¼ .0022), indicating adoption of this new practice in a high-volume center. 16 A review of 658 patients with T1 to T2 tumors planned for breast conservation treated at MD Anderson showed that prior to the publication of Z0011, 85% (53/62) of SLN-positive patients underwent completion ALND versus 24 % (10/42) after the publication of Z0011 (P < .001). 17 Additionally, a study from the Mayo Clinic also showed a reduction in the rate of completion ALND in patients with positive SLNs following Z0011's publication (83% to 62%; P < .01), and showed no difference in the number of sentinel nodes harvested before and after publication of Z0011.
18
A national survey sent to members of the American Society of Breast Surgeons in 2011 showed that 56.9% of respondents would not routinely perform ALND in patients with 1 or 2 positive SLNs who were planned to receive whole breast RT. Among respondents, 36% would consider omitting completion ALND in patients going on to receive accelerated partial breast radiation and 26.6% would omit ALND in patients not receiving any radiation. 19 A prior NCDB study, analyzing patients treated from 1998 to 2011 meeting Z0011 eligibility criteria, showed an increase in SLNB alone from 6.1% in 1998 to 23.0% in 2009 and to 56.0% in 2011 (P < .001). 20 It should be noted that this study utilized data from before 2012, which has been shown to under-report SLNB procedures either alone or with ALND. 10 Despite this noted issue with the data reporting at that time, this upward trend is concordant with our data that shows an SLNB-alone rate of 65.8% in 2012 and 72.1% in 2013.
Although there is increasing evidence that the results of Z0011 are being incorporated by the medical community, there has yet to be a large investigation into the wide scale adoption of Z0011 results until now. The primary aim of this study was to determine practice patterns of axillary management using the NCDB after the publication of Z0011 and any significant social, economic, or clinicopathologic factors that may influence these practices. National practice patterns of axillary management have adjusted in accordance with the results of ACOSOG Z0011. Our data shows an absolute reduction in the rate of completion ALND following SLNB among patients meeting Z0011 criteria from 2012 to 2013 from 34.2% to 27.9%. Nevertheless, 27.6% and 47.4% of patients with 1 and 2 positive sentinel nodes found on biopsy, respectively, undergo completion ALND, despite data showing no difference in outcomes. 15 Interestingly, clinical T stage was not associated with patients undergoing completion axillary dissection after positive SLNB. Given the demonstrated safety of avoiding an ALND for women with fewer than 3 positive SLNs who receive adjuvant whole breast RT, the updated practice guidelines recommending no completion dissection should be further encouraged. 
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Although the results of ACOSOG Z0011 provide valuable information regarding surgical management for this patient population, the issue of optimal radiation volumes remains an area for future investigation. Our data also shows the impact of facility type and location, race, insurance status and median income, and the number of positive sentinel nodes in patients who received RT to the breast and regional nodes. Although the Z0011 specified standard tangent radiation fields, many patients received high tangents, which traditionally encompass levels 1 and 2 of the axilla. 21 Review of radiation field design in a subset of patients in ACOSOG Z0011 showed that half received high tangents, 17% to 21% had supraclavicular RT, and 6% to 10% had a posterior axillary boost; however, these protocol violations were evenly distributed between both arms of the study. Additionally, the highest rates of deliberate nodal treatment were seen in those with multiple nodes. 8 The variation in radiation fields in ACOSOG Z0011 and our study may be owing to the lack of pathologic nodal data formerly provided by a completion axillary dissection. There did not seem to be any impact of treatment year (2012 vs. 2013) in our analysis, but practice appears to vary significantly depending on the type of center patients are treated at, with significantly greater amounts of patients in community practices receiving axillary nodal coverage as part of the RT course. There are no official guidelines by the American Society for Radiation Oncology regarding radiation treatment volumes for patients with low-volume axillary disease. Given the wide variation in radiation treatment volumes seen in the ACOSOG Z0011 trial, further efforts are needed to determine the optimal design of treatment fields. 
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The present analysis has several important limitations, the most important being that it is retrospective and non-randomized, subject to selection bias, or influenced by variables that cannot be controlled for in the NCDB. Owing to the inherent design of the NCDB, it is not possible to confirm treatment use coding data with individual patient data as data is only reported in the aggregate. Data representative of institutional treatment but not an individual surgeon or radiation oncologist treating breast cancer is used. Furthermore, the NCDB definition of radiation to the breast and lymph nodes implies a deliberate attempt to include regional lymph nodes in the treatment of the breast but does not specify whether high tangents or a supraclavicular field are used; therefore, either treatment field technique could have been utilized to include regional nodal volumes.
Conclusion
Despite the proven safety and efficacy of SLNB, almost 10% of patients with clinical T1-2N0 breast cancer are undergoing upfront ALND, suggesting that the adoption of NSABP B-32 remains ongoing. For patients meeting ACOSOG Z0011 criteria, nearly onethird of patients received a completion axillary dissection, despite the low risk of axillary recurrence and lack of clinical benefit. Finally, owing to large variations in radiation field design, further research and consensus guidelines are warranted in this post-Z0011 era.
Clinical Practice Points
The seminal ACOSOG Z0011 trial published in 2011 led to the recommendation for no additional axillary surgery beyond SLNB for women with clinical T1-T2N0 breast cancer who undergo SLNB and have 1 to 2 positive SLNs going on to undergo whole-breast RT following breast conservation surgery. Results from the NCDB show that, from 2012 to 2013, the rate of upfront SLNB has increased by 1.3%, whereas the rate of completion ALND for patients with 1 to 2 positive SLNs decreased 6.2%. For patients who receive SLNB only with 1 to 2 positive nodes who go on to receive adjuvant RT, 63.4% receive whole breast RT and 36.6% receive whole breast and nodal RT. 
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Nationwide practice patterns continue to evolve; however, many patients still receive axillary dissection. There remains significant variation in radiation field design in the adjuvant setting, warranting further research in this area.
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